Amori, R.E., Lau, J. and Pittas, A.G. (2007) ‘Efficacy and Safety of Incretin Therapy in Type 2 Diabetes’, JAMA, 298(2). Available at: https://doi.org/10.1001/jama.298.2.194.
Amy Kennedy (2013) ‘Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis’, PLoS ONE, 8(3). Available at: https://doi.org/doi: 10.1371/journal.pone.0058861.
Anderson, B., Funnell, M., and American Diabetes Association (2005) The art of empowerment: stories and strategies for diabetes educators. 2nd ed. Alexandria, Va: American Diabetes Association.
Anthony H. Barnett, Jenny Grice (2013) New Mechanisms in Glucose Control. BMJ Books; 1 edition. Available at: http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133.
‘[ARCHIVED CONTENT] Medicines management: Everybody’s business : Department of Health - Publications and statistics’ (no date). Available at: http://webarchive.nationalarchives.gov.uk/20080205142458/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082200.
Ashwell, S.G. et al. (2006) ‘Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes’, Diabetic Medicine, 23(3), pp. 285–292. Available at: https://doi.org/10.1111/j.1464-5491.2005.01781.x.
Atkinson, M.A. (2012) ‘The Pathogenesis and Natural History of Type 1 Diabetes’, Cold Spring Harbor Perspectives in Medicine, 2(11), pp. a007641–a007641. Available at: https://doi.org/10.1101/cshperspect.a007641.
Avery, L. et al. (2012) ‘Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions’, Diabetes Care, 35(12), pp. 2681–2689. Available at: https://doi.org/10.2337/dc11-2452.
Bailey, C.J. et al. (2010) ‘Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial’, The Lancet, 375(9733), pp. 2223–2233. Available at: https://doi.org/10.1016/S0140-6736(10)60407-2.
Barry, V.W. et al. (2014) ‘Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis’, Progress in Cardiovascular Diseases, 56(4), pp. 382–390. Available at: https://doi.org/10.1016/j.pcad.2013.09.002.
Bennett, W.L. et al. (2011) ‘Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations’, Annals of Internal Medicine, 154(9). Available at: https://doi.org/10.7326/0003-4819-154-9-201105030-00336.
Bethel, M.A. et al. (2017) ‘Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS)’, Diabetes Care [Preprint]. Available at: https://doi.org/10.2337/dc16-1135.
Beverley M Shields (2015) ‘Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature’, BMJ Open, 5(11). Available at: https://doi.org/doi: 10.1136/bmjopen-2015-009088.
Birkeland, K.I. (2015) ‘Hyperglycaemia in pregnancy: still a lot to learn’, The Lancet Diabetes & Endocrinology, 3(10), pp. 752–753. Available at: https://doi.org/10.1016/S2213-8587(15)00282-X.
Bretzel, R.G. et al. (2008) ‘Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial’, The Lancet, 371(9618), pp. 1073–1084. Available at: https://doi.org/10.1016/S0140-6736(08)60485-7.
Brown, J. et al. (1996) ‘Lifestyle interventions for the treatment of women with gestational diabetes’, in Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd. Available at: https://doi.org/10.1002/14651858.CD011970.pub2.
Buse, J.B. et al. (2009) ‘Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)’, The Lancet, 374(9683), pp. 39–47. Available at: https://doi.org/10.1016/S0140-6736(09)60659-0.
Buse, J.B. et al. (2010) ‘DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks’, Diabetes Care, 33(6), pp. 1255–1261. Available at: https://doi.org/10.2337/dc09-1914.
Buse, J.B. et al. (2011) ‘Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes’, Annals of Internal Medicine, 154(2). Available at: https://doi.org/10.7326/0003-4819-154-2-201101180-00300.
Capehorn, M. et al. (2017) ‘Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia )’, Diabetic Medicine [Preprint]. Available at: https://doi.org/10.1111/dme.13357.
Carver, C. (2006) ‘Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes’, The Diabetes Educator, 32(6), pp. 910–917. Available at: https://doi.org/10.1177/0145721706294259.
Celia G. Walker (2015) ‘Modelling the Interplay between Lifestyle Factors and Genetic Predisposition on Markers of Type 2 Diabetes Mellitus Risk’, PLoS ONE, 10(7). Available at: https://doi.org/doi: 10.1371/journal.pone.0131681.
Chatterjee, S. and Davies, M. (2015) ‘Type 2 diabetes: recent advances in diagnosis and management’, Prescriber, 26(10), pp. 15–21. Available at: https://doi.org/10.1002/psb.1355.
Chimen, M. et al. (2012) ‘What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review’, Diabetologia, 55(3), pp. 542–551. Available at: https://doi.org/10.1007/s00125-011-2403-2.
Choudhary, P. et al. (2012) ‘Islet cell transplantation: current status in the UK (2012)’, Practical Diabetes, 29(7), pp. 280–285. Available at: https://doi.org/10.1002/pdi.1707.
Copeland, K.C. et al. (2013) ‘Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents’, PEDIATRICS, 131(2), pp. 364–382. Available at: https://doi.org/10.1542/peds.2012-3494.
Courtney, H. et al. (2017) ‘Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists’, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Volume 10, pp. 79–87. Available at: https://doi.org/10.2147/DMSO.S126763.
Crasto, W., Jarvis, J. and Davies, M.J. (2016a) Handbook of insulin therapies. Switzerland: Adis. Available at: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745.
Crasto, W., Jarvis, J. and Davies, M.J. (2016b) Handbook of insulin therapies. Switzerland: Adis. Available at: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745.
Crasto, W., Jarvis, J. and Davies, M.J. (2016c) Handbook of insulin therapies. Switzerland: Adis. Available at: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745.
Crasto, W., Jarvis, J. and Davies, M.J. (2016d) Handbook of insulin therapies. Switzerland: Adis. Available at: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745.
Crasto, W., Jarvis, J. and Davies, M.J. (2016e) Handbook of insulin therapies. Switzerland: Adis. Available at: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745.
Crasto, W., Jarvis, J. and Davies, M.J. (2016f) Handbook of insulin therapies. Switzerland: Adis. Available at: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745.
Daly, H. et al. (2015) ‘Development of a self-management education module for those with type 2 diabetes on injectable therapies’, Practical Diabetes, 32(8), pp. 305–310a. Available at: https://doi.org/10.1002/pdi.1979.
Davies, M. et al. (2005) ‘Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine’, Diabetes Care, 28(6), pp. 1282–1288. Available at: https://doi.org/10.2337/diacare.28.6.1282.
Davies, M. et al. (2017) ‘Introduction of biosimilar insulins in Europe’, Diabetic Medicine, 34(10), pp. 1340–1353. Available at: https://doi.org/10.1111/dme.13400.
Davies, M.J. et al. (2008) ‘Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial’, BMJ, 336(7642), pp. 491–495. Available at: https://doi.org/10.1136/bmj.39474.922025.BE.
Davies, M.J. and Chatterjee, S. (2017) ‘Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care’, Nature Reviews Endocrinology, 13(6), pp. 317–318. Available at: https://doi.org/10.1038/nrendo.2017.41.
Deacon, C.F. and Lebovitz, H.E. (2016) ‘Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas’, Diabetes, Obesity and Metabolism, 18(4), pp. 333–347. Available at: https://doi.org/10.1111/dom.12610.
Dhatariya, K.K., Skedgel, C. and Fordham, R. (2017) ‘The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use’, Diabetic Medicine, 34(10), pp. 1361–1366. Available at: https://doi.org/10.1111/dme.13427.
Diamant, M. et al. (2010a) ‘Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial’, The Lancet, 375(9733), pp. 2234–2243. Available at: https://doi.org/10.1016/S0140-6736(10)60406-0.
Diamant, M. et al. (2010b) ‘Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial’, The Lancet, 375(9733), pp. 2234–2243. Available at: https://doi.org/10.1016/S0140-6736(10)60406-0.
Dungan, K.M. et al. (2014) ‘Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial’, The Lancet, 384(9951), pp. 1349–1357. Available at: https://doi.org/10.1016/S0140-6736(14)60976-4.
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials- ClinicalKey (no date). Available at: https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858717301043?returnurl=null&referrer=null.
‘Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes’ (2016) New England Journal of Medicine, 375(18), pp. 1799–1802. Available at: https://doi.org/10.1056/NEJMc1611290.
Evans, M. et al. (2011) ‘A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations’, Diabetes, Obesity and Metabolism, 13(8), pp. 677–684. Available at: https://doi.org/10.1111/j.1463-1326.2011.01395.x.
Frandsen, C.S.S. and Madsbad, S. (2014) ‘Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review’, Diabetic Medicine, 31(11), pp. 1293–1300. Available at: https://doi.org/10.1111/dme.12561.
Funnell, M.M. (2007) ‘Overcoming Barriers to the Initiation of Insulin Therapy’, Clinical Diabetes, 25(1), pp. 36–38. Available at: https://doi.org/10.2337/diaclin.25.1.36.
Gallwitz, B. et al. (2012) ‘2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial’, The Lancet, 380(9840), pp. 475–483. Available at: https://doi.org/10.1016/S0140-6736(12)60691-6.
Garber, A.J. et al. (2006) ‘Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)’, Diabetes, Obesity and Metabolism, 8(1), pp. 58–66. Available at: https://doi.org/10.1111/j.1463-1326.2005.00563.x.
Garber, A.J. et al. (2007) ‘Premixed insulin treatment for type 2 diabetes: analogue or human?’, Diabetes, Obesity and Metabolism, 9(5), pp. 630–639. Available at: https://doi.org/10.1111/j.1463-1326.2006.00654.x.
Garber, A.J. et al. (2012) ‘Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial’, The Lancet, 379(9825), pp. 1498–1507. Available at: https://doi.org/10.1016/S0140-6736(12)60205-0.
Gough, S.C.L. (2007) ‘A review of human and analogue insulin trials’, Diabetes Research and Clinical Practice, 77(1), pp. 1–15. Available at: https://doi.org/10.1016/j.diabres.2006.10.015.
Gough, S.C.L. et al. (2013) ‘Insulin degludec: overview of a novel ultra long-acting basal insulin’, Diabetes, Obesity and Metabolism, 15(4), pp. 301–309. Available at: https://doi.org/10.1111/dom.12052.
Grammes, J. et al. (2017) ‘Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus’, Diabetic Medicine [Preprint]. Available at: https://doi.org/10.1111/dme.13506.
Gray, L.J. et al. (2012) ‘Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance’, Diabetologia, 55(12), pp. 3238–3244. Available at: https://doi.org/10.1007/s00125-012-2725-8.
Gray, L.J. et al. (2014) ‘External validation of two diabetes risk scores in a young UK South Asian population’, Diabetes Research and Clinical Practice, 104(3), pp. 451–458. Available at: https://doi.org/10.1016/j.diabres.2014.03.018.
Green, J.B. et al. (2015) ‘Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, 373(3), pp. 232–242. Available at: https://doi.org/10.1056/NEJMoa1501352.
Gururaj Setty, S. et al. (2016a) ‘New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes’, Postgraduate Medical Journal, 92(1085), pp. 152–164. Available at: https://doi.org/10.1136/postgradmedj-2015-133716.
Gururaj Setty, S. et al. (2016b) ‘New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes’, Postgraduate Medical Journal, 92(1085), pp. 152–164. Available at: https://doi.org/10.1136/postgradmedj-2015-133716.
Hadjiconstantinou, M. et al. (2016) ‘Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis’, Journal of Medical Internet Research, 18(10). Available at: https://doi.org/10.2196/jmir.5991.
Hartman, Y.A.W. et al. (2017) ‘Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior’, Diabetes Care, 40(9), pp. e120–e121. Available at: https://doi.org/10.2337/dc17-0787.
Heinonen, I. et al. (2013) ‘Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study’, BMJ Open, 3(6). Available at: https://doi.org/10.1136/bmjopen-2013-002901.
Heller, S.R. et al. (2004) ‘Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes’, Diabetic Medicine, 21(7), pp. 769–775. Available at: https://doi.org/10.1111/j.1464-5491.2004.01244.x.
Henson, Joseph (2014) ‘Associations of Sedentary Time with Fat Distribution in a High-Risk Population.’ Available at: https://lra.le.ac.uk/handle/2381/32505.
Hermansen, K. et al. (2006) ‘A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes’, Diabetes Care, 29(6), pp. 1269–1274. Available at: https://doi.org/10.2337/dc05-1365.
Holman, R.R. et al. (2007) ‘Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes’, New England Journal of Medicine, 357(17), pp. 1716–1730. Available at: https://doi.org/10.1056/NEJMoa075392.
Holman, R.R. and Turner, R.C. (1985) ‘A Practical Guide to Basal and Prandial Insulin Therapy’, Diabetic Medicine, 2(1), pp. 45–53. Available at: https://doi.org/10.1111/j.1464-5491.1985.tb00592.x.
Home, P.D. (2012) ‘The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences’, Diabetes, Obesity and Metabolism, 14(9), pp. 780–788. Available at: https://doi.org/10.1111/j.1463-1326.2012.01580.x.
Horvath, K. et al. (1996a) ‘Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus’, in Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd. Available at: https://doi.org/10.1002/14651858.CD005613.pub3.
Horvath, K. et al. (1996b) ‘Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus’, in Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd. Available at: https://doi.org/10.1002/14651858.CD005613.pub3.
Htike, Z.Z. et al. (2016) ‘Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care’, British Journal of Diabetes, 16(3). Available at: https://doi.org/10.15277/bjd.2016.091.
Htike, Z.Z. et al. (2017a) ‘Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis’, Diabetes, Obesity and Metabolism, 19(4), pp. 524–536. Available at: https://doi.org/10.1111/dom.12849.
Htike, Z.Z. et al. (2017b) ‘Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis’, Diabetes, Obesity and Metabolism, 19(4), pp. 524–536. Available at: https://doi.org/10.1111/dom.12849.
Inzucchi, S.E. et al. (2015) ‘Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes’, Diabetes Care, 38(1), pp. 140–149. Available at: https://doi.org/10.2337/dc14-2441.
Ismail-Beigi, F. (2012) ‘Glycemic Management of Type 2 Diabetes Mellitus’, New England Journal of Medicine, 366(14), pp. 1319–1327. Available at: https://doi.org/10.1056/NEJMcp1013127.
John M Jakicic (2005) ‘Physical activity considerations for the treatment and prevention of obesity’, The American Journal of Clinical Nutrition, 82(1), pp. 226S-229S. Available at: http://ajcn.nutrition.org/content/82/1/226S.
Johnston, B.C. et al. (2014) ‘Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults’, JAMA, 312(9). Available at: https://doi.org/10.1001/jama.2014.10397.
Jones, A.G. and Hattersley, A.T. (2013) ‘The clinical utility of C-peptide measurement in the care of patients with diabetes’, Diabetic Medicine, 30(7), pp. 803–817. Available at: https://doi.org/10.1111/dme.12159.
Kamlesh Khunti (2015) ‘Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes’, PLoS ONE, 10(9). Available at: https://doi.org/doi: 10.1371/journal.pone.0135702.
Kenneth Hodson (2010) ‘Gestational diabetes: emerging concepts in pathophysiology’, Obstetric Medicine, 3(4). Available at: https://doi.org/doi: 10.1258/om.2010.100025.
Latika Sahu (2009) ‘Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy’, Obstetric Medicine, 2(4). Available at: https://doi.org/doi: 10.1258/om.2009.080049.
Lee, I.-M. (2010) ‘Physical Activity and Weight Gain Prevention’, JAMA, 303(12). Available at: https://doi.org/10.1001/jama.2010.312.
Leff, D.R. and Heath, D. (2009) ‘Surgery for obesity in adulthood’, BMJ, 339(sep22 1), pp. b3402–b3402. Available at: https://doi.org/10.1136/bmj.b3402.
Levin, P.A. et al. (2017) ‘Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research’, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Volume 10, pp. 123–139. Available at: https://doi.org/10.2147/DMSO.S130834.
‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’ (2016) New England Journal of Medicine, 375(18), pp. 1797–1799. Available at: https://doi.org/10.1056/NEJMc1611289.
Mäkimattila, S., Nikkilä, K. and Yki-Järvinen, H. (1999) ‘Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus’, Diabetologia, 42(4), pp. 406–412. Available at: https://doi.org/10.1007/s001250051172.
Marre, M. et al. (2009) ‘Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)’, Diabetic Medicine, 26(3), pp. 268–278. Available at: https://doi.org/10.1111/j.1464-5491.2009.02666.x.
Marso, S.P., Daniels, G.H., et al. (2016a) ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, 375(4), pp. 311–322. Available at: https://doi.org/10.1056/NEJMoa1603827.
Marso, S.P., Daniels, G.H., et al. (2016b) ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, 375(4), pp. 311–322. Available at: https://doi.org/10.1056/NEJMoa1603827.
Marso, S.P., Bain, S.C., et al. (2016) ‘Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes’, New England Journal of Medicine, 375(19), pp. 1834–1844. Available at: https://doi.org/10.1056/NEJMoa1607141.
Merlin C. Thomas (2016) ‘Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment’, Diabetes Therapy, 7(3). Available at: https://doi.org/doi: 10.1007/s13300-016-0189-4.
Michael Riddell (2009) ‘Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring’, Journal of diabetes science and technology (Online), 3(4). Available at: https://doi.org/doi: 10.1177/193229680900300439.
Min, S.H. et al. (2017) ‘Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis’, Diabetes/Metabolism Research and Reviews, 33(1). Available at: https://doi.org/10.1002/dmrr.2818.
‘Minimizing Hypoglycemia in Diabetes: Table 1’ (2015) Diabetes Care, 38(8), pp. 1583–1591. Available at: https://doi.org/10.2337/dc15-0279.
Mishriky, B.M., Cummings, D.M. and Tanenberg, R.J. (2015a) ‘The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis’, Diabetes Research and Clinical Practice, 109(2), pp. 378–388. Available at: https://doi.org/10.1016/j.diabres.2015.05.025.
Mishriky, B.M., Cummings, D.M. and Tanenberg, R.J. (2015b) ‘The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis’, Diabetes Research and Clinical Practice, 109(2), pp. 378–388. Available at: https://doi.org/10.1016/j.diabres.2015.05.025.
Moreno-Castilla, C., Mauricio, D. and Hernandez, M. (2016) ‘Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus’, Current Diabetes Reports, 16(4). Available at: https://doi.org/10.1007/s11892-016-0717-7.
Nathan, D.M. et al. (2006) ‘Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes’, Diabetes Care, 29(8), pp. 1963–1972. Available at: https://doi.org/10.2337/dc06-9912.
Nauck, M. et al. (2014) ‘Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)’, Diabetes Care, 37(8), pp. 2149–2158. Available at: https://doi.org/10.2337/dc13-2761.
Nauck, M. (2016) ‘Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors’, Diabetes, Obesity and Metabolism, 18(3), pp. 203–216. Available at: https://doi.org/10.1111/dom.12591.
Nauck, M.A. et al. (2007) ‘Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial’, Diabetes, Obesity and Metabolism, 9(2), pp. 194–205. Available at: https://doi.org/10.1111/j.1463-1326.2006.00704.x.
Nauck, M.A. and Meier, J.J. (2016) ‘The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions’, The Lancet Diabetes & Endocrinology, 4(6), pp. 525–536. Available at: https://doi.org/10.1016/S2213-8587(15)00482-9.
Nissen, S.E. and Wolski, K. (2007) ‘Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes’, New England Journal of Medicine, 356(24), pp. 2457–2471. Available at: https://doi.org/10.1056/NEJMoa072761.
Nolan, C.J. et al. (2015) ‘Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes’, Diabetes, 64(3), pp. 673–686. Available at: https://doi.org/10.2337/db14-0694.
Paul Craddy (2014) ‘Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison’, Diabetes Therapy, 5(1). Available at: https://doi.org/doi: 10.1007/s13300-014-0061-3.
Persaud, S.J. and Jones, P.M. (2016) ‘A Wake-up Call for Type 2 Diabetes?’, New England Journal of Medicine, 375(11), pp. 1090–1092. Available at: https://doi.org/10.1056/NEJMcibr1607950.
Postnatal testing following gestational diabetes- ClinicalKey (no date). Available at: https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858715003228?returnurl=null&referrer=null.
‘Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes’ (4AD). Available at: https://www.youtube.com/watch?v=AhhWTmEFuag.
Qin, L. et al. (2010) ‘Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data’, European Journal of Epidemiology, 25(1), pp. 5–12. Available at: https://doi.org/10.1007/s10654-009-9395-y.
Raskin, P. et al. (2005) ‘Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs’, Diabetes Care, 28(2), pp. 260–265. Available at: https://doi.org/10.2337/diacare.28.2.260.
Resources and tools (no date a). Available at: http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/78:global-guideline-for-managing-older-people-with-type-2-diabetes.html.
Resources and tools (no date b). Available at: http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/79:global-guideline-for-type-2-diabetes.html.
Resources and tools (no date c). Available at: http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/80:the-global-idf-ispad-guidelines-for-diabetes-in-childhood-and-adolescence.html.
Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein (2016) Textbook of Diabetes. John Wiley. Available at: https://ebookcentral-proquest-com.ezproxy4.lib.le.ac.uk/lib/leicester/reader.action?docID=4769056.
Richter, B. and Neises, G. (1996) ‘“Human” insulin versus animal insulin in people with diabetes mellitus’, in Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd. Available at: https://doi.org/10.1002/14651858.CD003816.pub2.
Riddle, M.C. et al. (2013) ‘Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)’, Diabetes Care, 36(9), pp. 2489–2496. Available at: https://doi.org/10.2337/dc12-2454.
Rinki Murphy (2015) ‘Monogenic diabetes and pregnancy’, Obstetric Medicine, 8(3). Available at: https://doi.org/doi: 10.1177/1753495X15590713.
Rizos, C.V., Kei, A. and Elisaf, M.S. (2016) ‘The current role of thiazolidinediones in diabetes management’, Archives of Toxicology, 90(8), pp. 1861–1881. Available at: https://doi.org/10.1007/s00204-016-1737-4.
Rosenstock, J. et al. (2008) ‘A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes’, Diabetologia, 51(3), pp. 408–416. Available at: https://doi.org/10.1007/s00125-007-0911-x.
Rosenstock, J. et al. (2013) ‘Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)’, Diabetes Care, 36(10), pp. 2945–2951. Available at: https://doi.org/10.2337/dc12-2709.
Rotz, M.E. et al. (2015) ‘Implications of incretin-based therapies on cardiovascular disease’, International Journal of Clinical Practice, 69(5), pp. 531–549. Available at: https://doi.org/10.1111/ijcp.12572.
Ryder, B. et al. (2013) ‘ABCD position statement on GLP-1 based therapies and pancreatic damage’, Practical Diabetes, 30(9), pp. 388–391. Available at: https://doi.org/10.1002/pdi.1816.
S M Attard (2015) ‘Implications of iron deficiency/anemia on the classification of diabetes using HbA1c’, Nutrition & Diabetes, 5(6). Available at: https://doi.org/doi: 10.1038/nutd.2015.16.
Safety and insulin: Implementation of national guidance at a local level | Journal Content | Diabetesonthenet.com (no date). Available at: http://www.diabetesonthenet.com/journal-content/view/safety-and-insulin-implementation-of-national-guidance-at-a-local-level.
Sallis, J.F. et al. (2016) ‘Progress in physical activity over the Olympic quadrennium’, The Lancet, 388(10051), pp. 1325–1336. Available at: https://doi.org/10.1016/S0140-6736(16)30581-5.
Samuel, V.T. and Shulman, G.I. (2012) ‘Intergrating Mechanisms for Insulin Resistance: Common Threads and Missing Links’, Cell, 148(5), pp. 852–871. Available at: https://doi.org/10.1016/j.cell.2012.02.017.
Schauer, P.R. et al. (2012a) ‘Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes’, New England Journal of Medicine, 366(17), pp. 1567–1576. Available at: https://doi.org/10.1056/NEJMoa1200225.
Schauer, P.R. et al. (2012b) ‘Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes’, New England Journal of Medicine, 366(17), pp. 1567–1576. Available at: https://doi.org/10.1056/NEJMoa1200225.
Schauer, P.R. et al. (2017) ‘Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes’, New England Journal of Medicine, 376(7), pp. 641–651. Available at: https://doi.org/10.1056/NEJMoa1600869.
Schwartz, S.S. et al. (2016) ‘The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema’, Diabetes Care, 39(2), pp. 179–186. Available at: https://doi.org/10.2337/dc15-1585.
Simmons, R.K. et al. (2016) ‘A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study’, Health Technology Assessment, 20(64), pp. 1–86. Available at: https://doi.org/10.3310/hta20640.
Sivasubramaniyam, S., Amiel, S.A. and Choudhary, P. (2017) ‘Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range’, Diabetic Medicine, 34(10), pp. 1456–1460. Available at: https://doi.org/10.1111/dme.13438.
Sjöström, L. et al. (2004) ‘Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery’, New England Journal of Medicine, 351(26), pp. 2683–2693. Available at: https://doi.org/10.1056/NEJMoa035622.
Srinivasan, B.T. et al. (2008) ‘Recent advances in the management of type 2 diabetes mellitus: a review’, Postgraduate Medical Journal, 84(996), pp. 524–531. Available at: https://doi.org/10.1136/pgmj.2008.067918.
Srinivasan, B.T. and Davies, M. (2014) ‘Glycaemic management of type 2 diabetes’, Medicine, 42(12), pp. 711–717. Available at: https://doi.org/10.1016/j.mpmed.2014.09.011.
Srinivasan, P. et al. (2007) ‘Islet cell transplantation’, Postgraduate Medical Journal, 83(978), pp. 224–229. Available at: https://doi.org/10.1136/pgmj.2006.053447.
‘Standards of Medical Care in Diabetes--2015: Summary of Revisions’ (2015) Diabetes Care, 38(Supplement_1), pp. S4–S4. Available at: https://doi.org/10.2337/dc15-S003.
Steven, S. et al. (2016) ‘Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders’, Diabetes Care, 39(5), pp. 808–815. Available at: https://doi.org/10.2337/dc15-1942.
Steven, S. and Taylor, R. (2015) ‘Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes’, Diabetic Medicine, 32(9), pp. 1149–1155. Available at: https://doi.org/10.1111/dme.12722.
Stewart, Z.A. et al. (2016) ‘Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes’, New England Journal of Medicine, 375(7), pp. 644–654. Available at: https://doi.org/10.1056/NEJMoa1602494.
Swinnen, S.G. et al. (1996) ‘Insulin detemir versus insulin glargine for type 2 diabetes mellitus’, in Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd. Available at: https://doi.org/10.1002/14651858.CD006383.pub2.
Tanner, M. (2016) ‘Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia’, Annals of Internal Medicine, 165(4). Available at: https://doi.org/10.7326/ACPJC-2016-165-4-020.
Tao, L. et al. (2015) ‘Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial’, Diabetic Medicine, 32(7), pp. 907–919. Available at: https://doi.org/10.1111/dme.12711.
‘Type 2 diabetes in adults: management | Guidance and guidelines | NICE’ (no date). Available at: https://www.nice.org.uk/guidance/ng28.
Umpierre, D. (2011) ‘Physical Activity Advice Only or Structured Exercise Training and Association With HbA Levels in Type 2 Diabetes’, JAMA, 305(17). Available at: https://doi.org/10.1001/jama.2011.576.
Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care (no date). Available at: http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview.
Villani, M., de Courten, B. and Zoungas, S. (2017) ‘Emergency treatment of hypoglycaemia: a guideline and evidence review’, Diabetic Medicine, 34(9), pp. 1205–1211. Available at: https://doi.org/10.1111/dme.13379.
Vloemans, A.F. et al. (2017) ‘Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study’, Diabetic Medicine, 34(10), pp. 1470–1476. Available at: https://doi.org/10.1111/dme.13429.
Wanner, C. et al. (2016) ‘Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes’, New England Journal of Medicine, 375(4), pp. 323–334. Available at: https://doi.org/10.1056/NEJMoa1515920.
WHO 2011 Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus (no date). Available at: http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/.
Yeh, J.S., Kushner, R.F. and Schiff, G.D. (2016) ‘Obesity and Management of Weight Loss’, New England Journal of Medicine, 375(12), pp. 1187–1189. Available at: https://doi.org/10.1056/NEJMclde1515935.
Yki-Järvinen, H. et al. (2006) ‘Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study’, Diabetologia, 49(3), pp. 442–451. Available at: https://doi.org/10.1007/s00125-005-0132-0.
Young, L.A. and Buse, J.B. (2014) ‘GLP-1 receptor agonists and basal insulin in type 2 diabetes’, The Lancet, 384(9961), pp. 2180–2181. Available at: https://doi.org/10.1016/S0140-6736(14)61409-4.
Young-Hyman, D. et al. (2017) ‘Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140’, Diabetes Care, 40(2), p. 287.1-287. Available at: https://doi.org/10.2337/dc17-er02.
Zaccardi, F. et al. (2016) ‘Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective’, Postgraduate Medical Journal, 92(1084), pp. 63–69. Available at: https://doi.org/10.1136/postgradmedj-2015-133281.
Zinman, B. et al. (2011) ‘Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial’, The Lancet, 377(9769), pp. 924–931. Available at: https://doi.org/10.1016/S0140-6736(10)62305-7.
